Ultragenyx Pharmaceutical Inc. Stock
There is nearly no change for the Ultragenyx Pharmaceutical Inc. stock today. Compared to yesterday it only changed by -€0.020.
With 26 Buy predictions and not a single Sell prediction Ultragenyx Pharmaceutical Inc. is an absolute favorite of our community.
With a target price of 50 € there is potential for a 116.45% increase which would mean more than doubling the current price of 23.1 € for Ultragenyx Pharmaceutical Inc..
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.090% | -1.699% | -21.639% | -1.111% | 37.738% | -29.879% | -70.522% |
| Ligand Pharmaceuticals | 1.560% | -4.580% | -9.420% | 96.850% | 50.602% | 296.825% | 166.923% |
| United Therapeutics | 1.220% | -1.202% | -7.386% | 71.854% | 3.885% | 104.280% | 153.657% |
| Ionis Pharmaceuticals Inc. | 1.690% | 4.583% | -3.842% | 38.314% | -27.810% | 35.338% | 46.404% |
Comments
Ultragenyx Pharmaceutical (RARE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
